Pharmacological Blockade of the Chemokine Receptor CCR1 Protects Mice from Systemic Candidiasis of Hematogenous Origin | Zendy

Michail S. Lionakis | Zendy; Nathaniel D. Albert | Zendy; Muthulekha Swamydas | Zendy; ChyiChia Richard Lee | Zendy; Pius Loetscher | Zendy; Dimitrios P. Kontoyiannis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Blockade of the Chemokine Receptor CCR1 Protects Mice from Systemic Candidiasis of Hematogenous Origin

Author(s) -

Michail S. Lionakis,

Nathaniel D. Albert,

Muthulekha Swamydas,

ChyiChia Richard Lee,

Pius Loetscher,

Dimitrios P. Kontoyiannis

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02365-16

Subject(s) - ccr1 , systemic candidiasis , blockade , chemokine receptor , chemokine , immunology , medicine , receptor , biology , pharmacology , microbiology and biotechnology , inflammation , antifungal , corpus albicans

Systemic candidiasis is a leading cause of nosocomial bloodstream infection with a high mortality rate despite treatment. Immune-based strategies are needed to improve outcomes. We previously reported that genetic deficiency in the chemokine receptor CCR1 improves survival and ameliorates tissue damage inCandida -infected mice. Here, we found that treatment of immunocompetentCandida -infected mice with the CCR1-selective antagonist BL5923 improves survival, decreases the kidney fungal burden, and protects from renal tissue injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research